Positive CHMP Opinion for Abstral (Rapinyl) - 27/6/2008

Testosterone replacement study shows positive results in diabetic men from 2% testosterone gel - 18/6/2008

Update on Sancuso® US Regulatory Review Status - 2/6/2008

ProStrakan Annual Information Update - 27/5/2008

ProStrakan and JapanBridge Partner to Develop Sancuso in Japan, China & Parts of SE Asia - 23/5/2008

Result of resolutions passed at Annual General Meeting - 21/5/2008

ProStrakan announces Torrex Chiesi as partner for Xomolix in Austria and CEE - 19/5/2008

Interim Management Statement - 15/5/2008

ProStrakan announces positive results from pivotal US "Fortify" study on Fortigel (testosterone 2% gel) - 8/5/2008

Annual report and accounts - 28/4/2008

FDA Moves Sancuso PDUFA Date to mid-June - 23/4/2008

Xomolix Receives Additional Key European Approvals - 2/4/2008

ProStrakan Group plc Share Plans - 31/3/2008

ProStrakan Reports Further Progress in a Year of Significant Developments - 13/3/2008

Rapinyl Receives Swedish Marketing Authorisation - 7/3/2008

Board Change - 28/1/2008

Director/PDMR Shareholding - 14/1/2008

ProStrakan Reports Further Strong Progress in Pre-Close Update - 8/1/2008

Grant of awards and Options - 7/1/2008